Yanqun Xiang

11PUBLICATIONS
25CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Aug 25, 2026
Becotatug Vedotin Combined With Pucotenlimab in Platinum- and Immunotherapy-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma.

|Feb 10, 2026
Final survival analysis of induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma: a multicenter, randomized, phase 3 trial.

Xun Cao, Jia-Yu Zhou, Hao-Yang Huang

|Dec 15, 2025
Capecitabine combined with immunotherapy as maintenance therapy improves survival in recurrent/metastatic nasopharyngeal carcinoma: a retrospective cohort study.

Shui-Qing He, Ying Huang, Ze-Yu Zhao

|Oct 17, 2024
Single-cell transcriptome analysis reveals evolving tumour microenvironment induced by immunochemotherapy in nasopharyngeal carcinoma.

Yaofei Jiang, Weixin Bei, Wangzhong Li

|Jul 15, 2024
Efficacy and Safety of Re-Challenging PD-1 Inhibitors in Second-Line Treatment in Metastatic Nasopharyngeal Carcinoma Previously Treated with Chemotherapy and PD-1 Inhibitors.

Weixin Bei, Shuhui Dong, Guoying Liu

|Jun 19, 2024
Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial.

Guo-Ying Liu, Yan-Fang Ye, Yao-Fei Jiang

Pageof 2

Frequent Collaborators

3 joint publications

Wang-Zhong Li

2 joint publications

Guo-Ying Liu

2 joint publications

Guoying Liu

1 joint publications

Kui-Yuan Liu